Drug Search Results
More Filters [+]

Follitropin alfa

Alternative Names: follitropin alfa, afolia, follitropin alpha, gonal-f rff rediject, gonal-f, gonal-f rff, xm-17, xm17, xm 17, Ovaleap
Latest Update: 2024-11-08
Latest Update Note: Clinical Trial Update

Product Description

Follitropin alfa is a hormone identical to follicle-stimulating hormone (FSH) produced by the pituitary gland. FSH helps to develop eggs in the ovaries. (Sourced from: https://www.mayoclinic.org/drugs-supplements/follitropin-alfa-subcutaneous-route/description/drg-20063905)

Mechanisms of Action: CG Stimulant

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Merck KGaA
Company Location: GERMANY HRB 6164 I8
Company CEO: Belen Garijo
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Follitropin alfa

Countries in Clinic: Australia, China

Active Clinical Trial Count: 9

Highest Development Phases

Phase 3: Anovulation|Other|Polycystic Ovary Syndrome

Phase 1: Acute Respiratory Distress Syndrome|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recombinant-human FSH (Bemfola®) in the late follicular phase

P3

Active, not recruiting

Unknown

2019-11-16

2006-7041-83/hah

P1

Not yet recruiting

Acute Respiratory Distress Syndrome

None

CTR20210004

P1

Recruiting

Healthy Volunteers

None

CTR20212627

P1

Not yet recruiting

Polycystic Ovary Syndrome

None

Recent News Events